Regulatory Roundup, Week of November 19, 2012 - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Regulatory Roundup, Week of November 19, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

The United States Pharmacopeial Convention (USP) has announced a new drug naming policy to take affect May 1, 2013. USP worked on the new policy with FDA and industry stakeholders to clarify naming practices for medicines and make them more consistent. According to USP, “the policy will apply prospectively to drug product and compounded preparation monographs that appear in USP’s compendia of public quality standards—the United States Pharmacopeia and National Formulary (USP–NF).”  For more information, visit USP’s website at

USP has also announced its “Fifth Bioassay Workshop,” which will be held on Dec. 4-5, 2012 at USP headquarters in Rockville, MD. The workshop will focus on the development, monitoring, and validation of bioassays. Visit USP's website for more information.

FDA has made available, Guidance on Q11 Development and Manufacture of Drug Substances. FDA intends the guidance to “harmonize the scientific and technical principals relating to the description and justification of the development and manufacturing process of drug substances….”  

Also released by FDA on November 19, 2012 is Guidance for Industry, Electronic Source Data in Clinical Investigations.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here